Janssens M, Symoens J
J Hypertens Suppl. 1986 Dec;4(6):S115-8.
The antihypertensive properties and adverse reactions of ketanserin, nifedipine and methyldopa were compared in hypertensive patients aged above 50 years in two international studies. After a placebo run-in period, patients received for 3 months, either ketanserin or nifedipine retard in study 1, and either ketanserin or methyldopa in study 2. After 1 month of monotherapy, a diuretic was added if necessary. Study 1 had 117 subjects, with 119 in study 2. The changes in systolic and diastolic blood pressure were similar for ketanserin and nifedipine although more patients switched to combination therapy in the ketanserin group. The overall response rate was comparable with ketanserin and nifedipine (96% for both drugs). The decrease in diastolic blood pressure was significantly greater in the ketanserin group compared to methyldopa and more patients responded to ketanserin (82%) than to methyldopa (65%). No rebound hypertension was observed on discontinuation of therapy with any of the drugs. The total incidence of adverse reactions in monotherapy was lower with ketanserin than with nifedipine (34 and 47%) and similar for ketanserin and methyldopa (40 and 45%). For ketanserin no consistent adverse reaction pattern was seen.
在两项国际研究中，对50岁以上高血压患者比较了酮色林、硝苯地平和甲基多巴的降压特性及不良反应。经过安慰剂导入期后，在研究1中患者接受了3个月的酮色林或缓释硝苯地平治疗，在研究2中患者接受了3个月的酮色林或甲基多巴治疗。单药治疗1个月后，必要时加用利尿剂。研究1有117名受试者，研究2有119名受试者。酮色林和硝苯地平的收缩压和舒张压变化相似，尽管酮色林组有更多患者改用联合治疗。酮色林和硝苯地平的总体有效率相当（两种药物均为96%）。与甲基多巴相比，酮色林组舒张压下降更显著，对酮色林有反应的患者（82%）多于甲基多巴（65%）。停用任何一种药物治疗时均未观察到反跳性高血压。酮色林单药治疗时不良反应的总发生率低于硝苯地平（分别为34%和47%），与甲基多巴相似（分别为40%和45%）。对于酮色林，未观察到一致的不良反应模式。
